经验

InnoCare Pharma and Zenas BioPharma Announce License Agreement

October 8, 2025

Cooley advised InnoCare Pharma, a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing first-in-class and best-in-class drugs for the treatment of cancers and autoimmune diseases with unmet medical needs in China and worldwide, on its transformational license agreement with Zenas BioPharma, granting Zenas global development and commercialization rights to orelabrutinib for multiple sclerosis and across all therapeutic areas other than oncology.

Read more

Related contacts

Lila Hope
Partner, 帕罗奥图
叶明晖
律师
Peter Adams
Partner, 圣地亚哥
Aaron Pomeroy
Partner, 科罗拉多
Steve Przesmicki
Partner, 圣地亚哥
Julia R. Brinton
Special Counsel, 华盛顿特区
David Burns
Special Counsel, 华盛顿特区
Sharon Connaughton
Special Counsel, 华盛顿特区
Andrew Epstein
Special Counsel, Seattle
沈亨达
顾问律师, 上海
Robert Eisenbach
Of Counsel, 旧金山
Rachel Thorn
Of counsel, 纽约
Jameson Davis
Associate, 波士顿
Amanda Pacheco
Associate, 帕罗奥图
汪晨
律师, 上海
Denny Xu
Associate, 波士顿
Zhijing Yu
Associate, 新加坡

Related Practices & Industries

Full-Life Technologies Secures $77 Million Series C

September 29, 2025

Cooley advised Full-Life Technologies, a fully integrated global radiotherapeutics company, on its $77 million Series C financing.

Read more

Related contacts

陆培祥
合伙人, 新加坡
徐璨
顾问律师, 上海
Christopher Kimball
Partner, 华盛顿特区
Grant Schweikert
Special Counsel, 华盛顿特区
汪晨
律师, 上海

Related Practices & Industries

InnoCare and KeyMed Jointly Announce License Agreement With Prolium

January 20, 2025

Cooley represented Beijing Tiannuo Jiancheng Pharmaceutical Technology, a joint venture of a subsidiary of InnoCare Pharma (HKEX: 09969; SSE: 688428) and a subsidiary of KeyMed Biosciences (HKEX: 02162), in connection with a joint exclusive license agreement with Prolium Bioscience for the development and commercialization of ICP-B02 (CM355), a CD20xCD3 bispecific antibody.

Read more

Related contacts

Lila Hope
Partner, 帕罗奥图
叶明晖
律师
沈亨达
顾问律师, 上海
汪晨
律师, 上海
魏 乐天
法律顾问, 上海
Jameson Davis
Associate, 波士顿
Robert Eisenbach
Of Counsel, 旧金山
王滨
资深顾问, 帕罗奥图
徐璨
顾问律师, 上海

Related Practices & Industries

Angitia Biopharmaceuticals Announces $120 Million Series C

December 17, 2024

Cooley advised Angitia Biopharmaceuticals, a clinical-stage biotechnology company focused on the discovery and development of innovative therapeutics for serious musculoskeletal diseases, on its $120 million Series C.

Read more

Related contacts

陆培祥
合伙人, 新加坡
徐璨
顾问律师, 上海
刘毅铭
上海办事处主管合伙人, 上海
Chadwick Mills
Partner, 旧金山
Charlie Kim
Partner, 圣地亚哥
汪晨
律师, 上海
魏 乐天
法律顾问, 上海
Brandon Lefebvre
Quantitative Analyst, 波士顿

Related Practices & Industries

Chimagen Biosciences Announces Sale of CMG1A46 to GSK

October 29, 2024

Cooley advised Chimagen Biosciences, a privately held biotechnology company, on its agreement to sell CMG1A46, a clinical-stage dual CD19 and CD20-targeted T-cell engager (TCE), to GSK, a global biopharma company, for an upfront payment of $300 million, plus success-based development and commercial milestone payments totaling up to $550 million.

Read more

Related contacts

Marya Postner
Partner, 帕罗奥图
刘毅铭
上海办事处主管合伙人, 上海
公泽
律师, 上海
葛江扬
律师, 洛杉矶
徐璨
顾问律师, 上海
Christopher Kimball
Partner, 华盛顿特区
Rama Padmanabhan
Partner, 圣地亚哥
Aaron Pomeroy
Partner, 科罗拉多
Jonathan Rivinus
Partner, 科罗拉多
Rachel Thorn
Of counsel, 纽约
David Wilson
Partner, 伦敦
David Burns
Special Counsel, 华盛顿特区
Sharon Connaughton
Special Counsel, 华盛顿特区
Andrew Epstein
Special Counsel, Seattle
王滨
资深顾问, 帕罗奥图
Robert Eisenbach
Of Counsel, 旧金山
Robert Eisenbach
Of Counsel, 旧金山
Natasha Leskovsek
Of Counsel, 华盛顿特区
Eerik Kukebal
Associate, 伦敦
Amanda Pacheco
Associate, 帕罗奥图
Leo Spicer-Phelps
Partner, 伦敦
苏伦嘎
律师, 上海
汪晨
律师, 上海
Zhijing Yu
Associate, 新加坡
魏 乐天
法律顾问, 上海

Related Practices & Industries

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as "Cooley"). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction, and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. When advising companies, our attorney-client relationship is with the company, not with any individual. This content may have been generated with the assistance of artificial intelligence (Al) in accordance with our Al Principles, may be considered Attorney Advertising and is subject to our legal notices.